Gender-Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen

Autor: Annemieke C. Heijboer, Renate T. de Jongh, Guy T'Sjoen, Mariska C. Vlot, Martin den Heijer, Chantal M Wiepjes
Přispěvatelé: Internal medicine, AGEM - Endocrinology, metabolism and nutrition, APH - Health Behaviors & Chronic Diseases, Amsterdam Movement Sciences - Rehabilitation & Development, Laboratory Medicine, Amsterdam Movement Sciences - Restoration and Development, APH - Aging & Later Life, ACS - Diabetes & metabolism, Laboratory for Endocrinology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, AMS - Musculoskeletal Health
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Male
Endocrinology
Diabetes and Metabolism
TESTOSTERONE UNDECANOATE
Bone remodeling
chemistry.chemical_compound
0302 clinical medicine
Interquartile range
Bone Density
Medicine and Health Sciences
CIRCULATING SCLEROSTIN LEVELS
Orthopedics and Sports Medicine
Testosterone
VITAMIN-D
SCLEROSTIN
Estradiol
ESTROGEN
medicine.anatomical_structure
Female
Original Article
Bone Remodeling
Adult
medicine.medical_specialty
BODY-COMPOSITION
BONE TURNOVER MARKER
GENDER-AFFIRMING HORMONE TREATMENT
medicine.drug_class
030209 endocrinology & metabolism
SEX STEROIDS
METABOLISM
Transgender Persons
Bone resorption
GENDER‐AFFIRMING HORMONE TREATMENT
03 medical and health sciences
Internal medicine
medicine
Vitamin D and neurology
Humans
P1NP
BIOCHEMICAL MARKERS
Femoral neck
TRANSGENDER
business.industry
Androgen Antagonists
Original Articles
030104 developmental biology
Endocrinology
chemistry
Estrogen
Sex Reassignment Procedures
Sclerostin
MINERAL DENSITY
business
TO-FEMALE TRANSSEXUALS
Biomarkers
Zdroj: Vlot, M C, Wiepjes, C M, de Jongh, R T, T'Sjoen, G, Heijboer, A C & den Heijer, M 2019, ' Gender-Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen ', Journal of Bone Mineral Research, vol. 34, no. 10, pp. 1862-1872 . https://doi.org/10.1002/jbmr.3762
Journal of Bone Mineral Research, 34(10), 1862-1872
Journal of bone and mineral research, 34(10), 1862-1872. Wiley-Blackwell
Journal of Bone and Mineral Research
JOURNAL OF BONE AND MINERAL RESEARCH
ISSN: 1862-1872
1523-4681
0884-0431
DOI: 10.1002/jbmr.3762
Popis: Sex steroids play a key role in bone turnover and preserving BMD; hence, gender‐affirming hormone treatment (HT) in transgender people affects bone metabolism. Most studies have looked into the effect of HT on changes in BMD; however, they do not provide insights into changes in bone metabolism caused by HT. This study investigated changes in bone turnover markers (BTMs) and sclerostin, as well as their correlations with change in BMD in transwomen and transmen during the first year of HT. Transwomen received estradiol and antiandrogens; transmen received testosterone. Sclerostin; P1NP; alkaline phosphatase (ALP); CTx; and BMD of the total hip, the femoral neck, and the lumbar spine were evaluated at baseline and after 1 year of HT. There were 121 transwomen (median age 30 years, interquartile range [IQR] 24 to 41 years) and 132 transmen (median age 24 years, IQR 21 to 33 years) included in the study. In transwomen, ALP decreased in 19% (95% CI, –21 to–16), CTx in 11% (95% CI, –18 to–4), and sclerostin in 8% (95%CI, –13 to–4) of study participants after 1 year of HT. In contrast, in transmen P1NP, ALP, and sclerostin increased in 33% (95% CI, 24 to 42), 16% (95% CI, 12 to 20), and 15% (95% CI, 10 to 20) of study participants, respectively, after 1 year of HT. No age differences were seen in transwomen, whereas in transmen aged ≥50 years a decrease in all BTMs was found in contrast with the other age groups. These transmen had low estrogen concentration at the start of HT based on their postmenopausal state before the start of HT; their estradiol concentrations increased during testosterone treatment. Changes in BTMs and BMD were weakly correlated (correlation coefficient all
Databáze: OpenAIRE
Externí odkaz: